CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

1:14-cv-01236

Overview

Case Number 1:14-cv-01236
Filing Date 2014-09-25
Status Terminated
Termination Date 2015-10-07
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Laboratories Ltd. Operating Company

Represented By

1 Attorneys Listed

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Mylan Pharmaceuticals Inc. Operating Company

Represented By

1 Attorneys Listed

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Plaintiff

AbbVie Inc. Operating Company

Represented By

8 Attorneys Listed

Robert C. Stanley

Email: robert.stanley@finnegan.com

Mindy L. Ehrenfried

Email: mindy.ehrenfried@finnegan.com

Jonathan R. Davies

Email: jdavies@cooley.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Corinne Miller LaGosh

UNDELIVERABLE EMAIL 10/7/15

Barbara R. Rudolph

Email: barbara.rudolph@finnegan.com

Amanda K. Murphy

Email: amanda.murphy@finnegan.com

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 6 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (6 found):
U.S. Courts: 6
U.S. District Court 2017-01-13
1:17-cv-00047

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2015-10-02
1:15-cv-00889

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-09-05
1:14-cv-01137

AbbVie Inc. v. Hetero Labs Limited

Asserted Patent
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00959

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2013-06-14
1:13-cv-01072

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-05-15
1:13-cv-00852

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8691878
Solid pharmaceutical dosage form
Filed: 2012-11-12
Issued: 2014-04-08
Active (6.0 yrs remaining)
Expires: 2032-11-12

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 2 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
Letter to The Honorable Richard G. Andrews from Mary B. Graham regarding case status and Markman hearing. (Graham, Mary) (Entered: 11/12/2014)
Entry #13 • 2014-11-12 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the Complaint to November 5, 2014, filed by Mylan Laboratories Ltd., Mylan ...
Entry #β€” • 2014-10-22
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the Complaint to November 5, 2014 - filed by Mylan Laboratories Ltd., Mylan Pharmaceuticals ...
Entry #7 • 2014-10-21 Document →

Docket Entries

(30 total)
Pleading / Complaint

COMPLAINT filed against Mylan Laboratories Ltd., Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1595784.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A-D Part 1 of 2, # 2 Exhibit A-D Part 2 of 2, # 3 Civil Cover Sheet)(dmp, ) (Entered: 09/26/2014)

Entry #1 • 2014-09-25
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 09/26/2014)

Entry #2 • 2014-09-25
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: 8,691,878:8/25/2024, Pediatric exclusivity:2/25/2025. Thirty Month Stay Deadline: N/A (dmp, ) (Entered: 09/26/2014)

Entry #3 • 2014-09-25
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,691,878 B2;. (dmp, ) (Entered: 09/26/2014)

Entry #4 • 2014-09-25
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (dmp, ) (Entered: 09/26/2014)

Entry #5 • 2014-09-25
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc